Mercia Asset Management

Mercia Asset Management is a specialist asset manager based in the United Kingdom, focused on equity and debt investments to support the growth aspirations of regional businesses. The firm manages multiple funds, including venture capital funds dedicated to early-stage technology companies, particularly in the West Midlands. Mercia aims to provide a complete capital solution by investing across various asset classes, including venture and private equity. It emphasizes backing companies with strong growth potential and proprietary technology. The firm offers initial investments typically ranging from £50,000 to £250,000, with the capacity for follow-on investments up to £1 million per company. Mercia Asset Management also allows private investors to participate in high-growth technology companies through its Growth EIS Fund, benefiting from tax reliefs. Established in 1982, Mercia has established a reputation as a proactive partner for business owners, shareholders, and fund investors, aspiring to deliver superior returns.

Paul Arthur

Investment Director

Natalia Blagburn

Portfolio Director, NEVF and EIS

Chris Borrett

Investment Director

Ed Bradburn

Deputy Fund Principal

Ishaan Chilkoti

Partner

Andy Clough

Investment Manager

Brian Davidson

Operating Partner

Julian Dennard

Fund Principal, EIS / MEIF

Maurice Disasi

Investment Manager

Clive Downward

Investment Director

Martin Glanfield

CFO

Andy Green

Investment Director

Henry Hamilton

Investment Manager

Andy Heaton

Investment Manager

Stephen Johnson

Investment Director

Rafael Joseph

Investment Manager

Srikar Karri

Investment Manager

Warwick Ley

Investor and Operational Partner

Robin Lincoln

Operating Partner

Hugo Lough

Investment Director

Chris McCourt

Investment Director

Matthew Mead

Venture Partner

Kiran Mehta

Investment Manager

Jonny Nixon

Investment Director

Jan Oosthuizen

Investment Manager

Nigel Owens

Portfolio Director, VCT Funds

Mark Payton

CEO

Chris Pestell

Investment Director

Rebecca Pickering

Investment Manager

Mike Rogers

Investment Director

Peter Rooney

Investment Manager

Brijesh Roy

Investment Manager

William Schaffer

Investment Director

Peter Sorsby

Deputy Fund Principal - NPIF Debt

Paul Taberner

Managing Director, Mercia Debt Funds

Andy Tyas

Investment Manager

Angela Warner

Managing Director, Mercia Investments

Jason Warren

Partner, VCT Funds

Adam Watts

Investment Manager

Gary Whitaker

Investment Manager

Ian Wilson

Fund Principal

Stephen Windsor

Deputy Fund Principal

David Wright

Investment Manager

Past deals in Local

Locate Bio

Venture Round in 2021
Locate Bio Limited is a regenerative medicine company specializing in innovative solutions for tissue repair. The company has developed a platform utilizing Targeted, Orchestrated Signaling technology, which focuses therapeutic signals at the site of tissue injuries. This approach enhances the effectiveness of cell therapies and facilitates localized repair by providing a supportive structure for tissue regeneration. Locate Bio’s products are applicable across various clinical fields, including orthopedics, cardiology, neurology, dentistry, and reconstructive surgery. The company's offerings include thermally activated and injectable scaffolds that solidify within the body, enabling advanced pharmaceutical delivery and supporting tissue growth. Established in 2001 and based in Nottingham, United Kingdom, Locate Bio aims to address significant unmet clinical needs, primarily assisting surgeons in improving the quality of life for patients with challenging spinal conditions.

Locate Bio

Venture Round in 2020
Locate Bio Limited is a regenerative medicine company specializing in innovative solutions for tissue repair. The company has developed a platform utilizing Targeted, Orchestrated Signaling technology, which focuses therapeutic signals at the site of tissue injuries. This approach enhances the effectiveness of cell therapies and facilitates localized repair by providing a supportive structure for tissue regeneration. Locate Bio’s products are applicable across various clinical fields, including orthopedics, cardiology, neurology, dentistry, and reconstructive surgery. The company's offerings include thermally activated and injectable scaffolds that solidify within the body, enabling advanced pharmaceutical delivery and supporting tissue growth. Established in 2001 and based in Nottingham, United Kingdom, Locate Bio aims to address significant unmet clinical needs, primarily assisting surgeons in improving the quality of life for patients with challenging spinal conditions.

Locate Bio

Venture Round in 2018
Locate Bio Limited is a regenerative medicine company specializing in innovative solutions for tissue repair. The company has developed a platform utilizing Targeted, Orchestrated Signaling technology, which focuses therapeutic signals at the site of tissue injuries. This approach enhances the effectiveness of cell therapies and facilitates localized repair by providing a supportive structure for tissue regeneration. Locate Bio’s products are applicable across various clinical fields, including orthopedics, cardiology, neurology, dentistry, and reconstructive surgery. The company's offerings include thermally activated and injectable scaffolds that solidify within the body, enabling advanced pharmaceutical delivery and supporting tissue growth. Established in 2001 and based in Nottingham, United Kingdom, Locate Bio aims to address significant unmet clinical needs, primarily assisting surgeons in improving the quality of life for patients with challenging spinal conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.